AstraZeneca drug may halt development of world’s fourth leading cause of death

Share this article:
The main ingredient in AstraZeneca's inhaler treatment Pulmicort may help against the development of emphysema and other forms of lung disease, according to new research conducted on smokers with chronic obstructive pulmonary disease (COPD).
Data revealed that Pulmicort's active ingredient, budesonide, shows a 50 percent slower decline in lung density in smokers with COPD, compared to patients taking a placebo. The trial was carried out on 254 smokers with moderate to severe COPD, who were followed for two to four years, during which their lung density was measured. 
It is estimated that there are 600 million COPD sufferers worldwide, making it the world's fourth-leading cause of death. Emphysema, a condition in which lungs are irreversibly and permanently over-inflated, is a form of COPD.
AstraZeneca also markets the inhaler Symbicort for COPD, which combines Pulmicort's budesonide with a long-lasting bronchodilator, formoterol.
The company plans to launch Symbicort, which has experienced strong growth in Europe, in the U.S. for the treatment of asthma later this year.
Share this article:
You must be a registered member of MMM to post a comment.

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters